Table 4.
Clinical characteristics according to occurrence of early rebleeding event (mean ± SD) n (%)
| No rebleeding(n = 88) | Rebleeding(n = 13) | Total(n = 101) | P value | |
| Sex (male) | 27 (30.7) | 5 (38.5) | 32 (31.7) | 0.574 |
| Age (yr) | 64.25 ± 17.40 | 69.0 ± 13.97 | 64.86 ± 17.01 | 0.350 |
| Hemodynamic shock | 46 (52.3) | 7 (53.8) | 53 (52.5) | 0.916 |
| Helicobacter infection | 19 (21.6) | 3 (23.1) | 22 (21.8) | 0.904 |
| Hemoglobin (g/dL) | 8.61 ± 2.77 | 7.09 ± 2.02 | 8.41 ± 2.72 | 0.060 |
| Hemoglobin < 7 g/dL | 26 (29.5) | 7 (53.8) | 33 (32.7) | 0.081 |
| Blood urea nitrogen (mg/dL) | 39.81 ± 25.92 | 40.09 ± 33.50 | 39.84 ± 26.82 | 0.972 |
| Creatinine (mg/dL) | 1.26 ± 1.12 | 1.03 ± 0.83 | 1.23 ± 1.09 | 0.473 |
| Albumin (g/dL) | 2.97 ± 0.60 | 2.86 ± 0.47 | 2.96 ± 0.59 | 0.532 |
| Type 2 diabetes mellitus | 21 (23.9) | 3 (23.1) | 24 (23.8) | 0.950 |
| Hypertension | 38 (43.2) | 3 (23.1) | 41 (40.6) | 0.168 |
| Heart failure | 9 (10.2) | 2 (15.4) | 11 (10.9) | 0.577 |
| Ischemic heart disease | 17 (19.3) | 1 (7.7) | 18 (17.8) | 0.454 |
| Antiplatelet medication | 37 (42.0) | 7 (53.8) | 44 (43.6) | 0.423 |
| NSAID | 7 (8.0) | 2 (15.4) | 9 (8.9) | 0.380 |
| Multiple antiplatelet medications | 5 (5.7) | 2 (15.4) | 7 (6.9) | 0.221 |
| Steroid | 5 (5.7) | 1 (7.7) | 6 (5.9) | 0.572 |
| Melena | 50 (56.8) | 9 (69.2) | 59 (58.4) | 0.397 |
| Hematemesis | 51 (58.0) | 4 (30.8) | 55 (54.5) | 0.066 |
| Hematochezia | 5 (5.7) | 2 (15.4) | 7 (6.9) | 0.199 |
| Complete Rockall score | 6.73 ± 1.40 | 7.69 ± 1.03 | 6.86 ± 1.39 | 0.020 |
| Rockall score > 6 | 43 (48.9) | 12 (92.3) | 55 (54.5) | 0.003 |
| Somatostatin use | 41 (46.6) | 8 (61.5) | 49 (48.5) | 0.314 |
NSAID: Non-steroidal anti-inflammatory drug.